The Top Ten Things Every Clinician Should Know About Sacubitril/Valsartan

Sacubitril/valsartan is considered part of the backbone of guideline-recommended therapies for the management of patients with heart failure. In 2021, sacubitril/valsartan became the preferred treatment over an ACEi or ARB in patients with heart failure with reduced ejection fraction (HFrEF) because it reduces the risk of cardiovascular death and hospitalization for heart failure in nearly all adult patients with chronic heart failure. All clinicians should be familiar with the indications, dosing, safety, and monitoring of sacubitril/valsartan.  Affordability, access, and inappropriate dose titration remain major barriers to achieving optimal outcomes.

Guest Authors:  Jessica Wooster, PharmD, BCACP and Elizabeth Yett, PharmD, BCACP

Special Guest:  Dustin (DJ) Clark, PharmD, BCACP

Music by: Good Talk